Patched1 (PTCH1) is one of the key molecules involved in the Hedgehog (HH) signaling pathway and acts as the receptor of HH ligands. Additionally, PTCH1 inhibits the positive signal transductor Smoothened (SMO). Several PTCH1 splice variants are known but the functional differences among them are not clear. Here, we demonstrate the unique biological properties of the PTCH1 isoforms generated by alternative first exon usage. All isoforms examined worked as functional receptors of both Sonic HH and Desert HH. However, the signaling upregulated isoforms PTCH1-1B and -1C inhibited SMO and the pathway transcription factors glioma 1 (GLI1) and GLI2 to a higher extent than PTCH1-1 and -1Ckid. Moreover, in situ hybridizations allowed the detection of the Ptch1 isoforms in specific structures of the developing mouse embryo. Additionally, the differences in the N-terminal tail had a dramatic influence on the steady states of the proteins, with PTCH1-1B and -1C levels being significantly higher than PTCH1-1 and -1Ckid. This implies that the pronounced signaling inhibitory properties of PTCH1-1B and -1C may be mostly due to this high-protein expression rather than to intrinsic functional differences. Thus, our study supports a role of splicing variation and promoter choice for HH signaling regulation.
Introduction
Alternative splicing and alternative promoter usage are effective mechanisms for generating diverse gene products from the same genomic region. Recent highthroughput analysis has demonstrated that the majority of human genes are subjected to splicing variations (Kampa et al., 2004) . Thus, alternative splicing appears to be a major regulator of post-transcriptional modifications and may cause a significant change in the function of the encoded protein. By inactivating tumor suppressors or by a gain-of-function in proteins that promote abnormal cell growth, alteration of splicing may be involved in tumorigenesis. Additionally, another recent genome-wide analysis has revealed the presence of a large number of alternative promoters (Carninci et al., 2006) . Alternative transcription initiation may regulate tissue-or time-dependent expression due to a different response to transcription factors or by epigenetic changes. Moreover, it may regulate protein function by variations that could be generated in the N-terminal region (Hughes, 2006) .
The Hedgehog (HH) signaling pathway has important roles in diverse biological contexts, such as embryonic development and tumorigenesis (Kalderon, 2005) . Deregulation of HH signaling causes malformation and tumor formation, with the first example being basal cell carcinomas (BCC) (Johnson et al., 1996; Hahn et al., 1996b) . In a number of tumors that were recently found to include prostatic and pancreatic cancers, HH signaling is abnormally upregulated, and effective signaling inhibition can repress tumor growth and induce apoptosis (Sanchez et al., 2004) . Among core components of the HH pathway, the secreted ligand HH, the membrane receptor Patched (PTCH), the membrane signal transductor Smoothened (SMO) and the transcription factor Ci/glioma (GLI) are evolutionarily conserved from insects to mammals. However, there is only one secreted ligand (Hh), one receptor (Ptc) and one transcription factor (Ci) in Drosophila, whereas there are three secreted ligands, Sonic HH (SHH)/ Desert HH (DHH)/Indian HH (IHH), two receptors (PTCH1/2) and three transcription factors (GLI1/2/3) in mammals.
The PTCH mammalian paralogues, PTCH1 and PTCH2, have a high amino acid sequence identity (57%) (Carpenter et al., 1998; Smyth et al., 1999; Zaphiropoulos et al., 1999) , are target genes of HH signaling (Motoyama et al., 1998; Rahnama et al., 2004) , and are biochemically similar in their binding affinities with SHH, DHH, IHH and SMO (Carpenter et al., 1998) . However, PTCH2 cannot repress activation of the HH signaling pathway and Ptch2 knockout mice do not show significant phenotypes (Lee et al., 2006) . On the other hand, PTCH1 inhibits HH signaling activation and Ptch1 null mice die during embryogenesis (Goodrich et al., 1997; Hahn et al., 1998) . As loss of PTCH1 function by mutation or deletion causes tumor formation such as BCC, PTCH1 is categorized as a tumor-suppressor gene. PTCH1 has several known roles in the HH signaling pathway including (a) a receptor of HH proteins, (b) an inhibitor of SMO activation, (c) an inhibitor of GLI1 activation (Rahnama et al., 2006) and (d) a target gene of HH signaling. The regulation of SMO activity by PTCH1, depending on HH protein binding, is the core control system of the HH pathway, but the mechanism is not fully clarified yet.
Recent genome-wide RNAi screening indicated that splicing has a significant role in HH signaling regulation (Nybakken et al., 2005) . PTCH1 is reported to have at least four first exons, 1, 1A, 1B and 1C (Johnson et al., 1996; Hahn et al., 1996a, b; Kogerman et al., 2002; Shimokawa et al., 2004; Nagao et al., 2005) , and moreover undergoes exon skipping (Smyth et al., 1998; Nagao et al., 2005) or alternative exon insertion events (Uchikawa et al., 2006) . The alternative promoters for exons 1B and 1C have GLI1 binding sites, consequently HH signaling activation results in upregulation of both PTCH1-1B and -1C (Shimokawa et al., 2004) . These isoforms may thus work as mediators of the negative feedback loop, which characterizes HH signaling.
To determine whether the PTCH1 variants generated by the alternative promoters can work equivalently in the HH signaling pathway, we examined their biochemical properties. We find that the PTCH1 alternative promoters and first exons influence the expression pattern and the stability of the proteins as well as their capacity to act as inhibitors of HH signaling.
Results

Alternative splice variants of PTCH1-1C
In previous reports, we and others showed that PTCH1 has several first exons, with the expression of exons 1B and 1C being upregulated by HH signaling activation (Kogerman et al., 2002; Shimokawa et al., 2004; Å gren et al., 2004; Nagao et al., 2005) . However, the functional differences among the PTCH1 isoforms were not fully clarified. In this report, we focus on the alternative first exons 1, 1A, 1B and 1C that are expressed by the use of the corresponding promoters and compare the functions of the resulting protein isoforms (Figure 1a) . Initially, we screened a human cDNA panel with primers within these four first exons and exon 3 by polymerase chain reaction (PCR). We could not detect any novel splice variant that included exons 1, 1A or 1B (data not shown). However, this approach allowed the detection of tissue-specific expression of two novel alternative variants initiating at exon 1C. One, found in liver, had skipped exon 2 (PTCH1-1CDE2), and the other, detected in kidney, used an alternative 5 0 -splice site within exon 1C (PTCH1-1Ckid). We also found a third variant, which joined the alternative 5 0 -splice site within PTCH1 splice variants specific function T Shimokawa et al exon 1C directly to exon 3 (PTCH1-1CkidDE2, data not shown). The open reading frames (ORFs) of PTCH1-1CDE2 and PTCH1-1CkidDE2 were the same as the ORFs of the previously characterized variants PTCH1-1 and PTCH1-1A (Kogerman et al., 2002) . On the other hand, PTCH1-1Ckid had a fusion ORF, resulting from the joining of an upstream ORF to the PTCH1-1C ORF and consequently coded for a PTCH1 variant with a unique N-terminal tail. Thus, we determined to analyse the four distinct protein isoforms, PTCH1-1, PTCH1-1B, PTCH1-1C and PTCH1-1Ckid (Figure 1b and c).
To compare the capacity of PTCH-1Ckid to downregulate HH signaling relative to the other isoforms, we performed functional assays in NIH3T3 cells, which respond well to signaling activation, using a luciferase reporter construct containing eight repeats of the GLI binding sequence (8 Â GLIBS-luc) and the SMO-M2 expression construct as described before (Shimokawa et al., 2004) . PTCH1-1Ckid inhibited SMO-M2 activation similar to PTCH1-1C but not to the same extent as PTCH1-1B ( Figure 1d ). This result suggests that PTCH1-1Ckid also has the capacity to act as a negative regulator of HH signaling.
GLI activity suppression by the PTCH1 variants
In a previous report (Rahnama et al., 2006) , we demonstrated that the activity of GLI1 can be downregulated by PTCH1-1B without involvement of the canonical cascade of HH signaling events. To clarify the role of the different PTCH1 variants in this novel regulatory mechanism, we co-transfected the GLI1 expression construct with the individual PTCH1 isoforms (Figure 2a ). PTCH1-1B and -1C completely blocked the GLI1 activity. PTCH1-1 and -1Ckid also strongly inhibited GLI1. In all cases, the inhibition of GLI1 activity by the PTCH1 isoforms was found to be independent of treatment with the SMO inhibitor, cyclopamine, at concentrations that we previously showed to block fully HH signaling activation (Rahnama et al., 2006) . Similar results were obtained when we used NIH3T3 instead of Hek293 cells (data not shown).
As GLI2 is a main transcription factor mediating HH signaling, we also examined the capacity of the PTCH1 variants against GLI2 activity (Figure 2b ). PTCH1-1B and -1C completely repressed full-length GLI2 but only partially repressed the active form of GLI2 that lacks the amino terminal region (Roessler et al., 2005) . PTCH1-1 and PTCH1-1Ckid partially inhibited both the full-length and the active form of GLI2. The effects on active GLI2 were weaker than those of PTCH1-1B or PTCH1-1C.
These results expand on the possible role of PTCH1 in HH signal transduction. Isoforms of PTCH1 may negatively regulate HH signaling not only at initial -SMO-but also at later -GLI-steps.
Functional comparison of PTCH1 isoforms as HH protein receptors
To examine the capacity of the PTCH1 variants to act as functional receptors of HH proteins, we first co-transfected an SHH-N expression construct with the PTCH1 isoforms into NIH3T3 cells. PTCH1-1B appeared to partially repress this activation, but the other PTCH1 isoforms could not inhibit the activity of exogenous SHH-N, as determined by the 8 Â GLIBS-luc reporter construct (Figure 3a) . To analyse the effects of the PTCH1 variants in a more natural context, we also transfected the isoforms into Ptch1 À/À mouse embryonic fibroblasts (MEF) cells (Figure 3b ). The HH signaling pathway is constantly activated in these Ptch1 À/À MEFs, and all PTCH1 isoforms but not PTCH2 inhibited the luciferase activity of the reporter construct. SHH-N or DHH-N co-transfection completely released the inhibition from PTCH1-1. However, the SHH-N release of the inhibitory effects of PTCH1-1B, -1C or -1Ckid allowed only 62, 63 or 75% activation, respectively. Additionally, DHH-N reconstituted only 52, 82 or 83% of the activity in the case of PTCH1-1B, -1C or -1Ckid, respectively. These results suggest that all PTCH1 isoforms, but not PTCH2, have the capacity to act as a functional receptor for SHH and DHH. Additionally, these data indicate that PTCH1-1B has the strongest effects as a sustained signaling inhibitor. 
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We also examined the subcellular localization of the PTCH1 variants and their capacity to internalize SHH-N (Supplementary Figure S1) . Exogenous PTCH1 expression in Ptch1 À/À MEFs revealed that there were no significant differences in subcellular distribution among the PTCH1 isoforms. Incubation with SHH-N allowed PTCH1 variant-mediated peptide internalization, with no dramatic changes in PTCH1 subcellular localization.
Moreover, we transfected the PTCH1 expression constructs with and without SHH-N and examined the PTCH1 protein levels by Western blotting (Figure 4a ). Hek293 cells were used in this assay, as their transfection efficiency of over 95% allows clear signal detection compared with NIH3T3 cells that have an efficiency of less that 25% (unpublished observations). Even though we transfected the same amount of PTCH1 constructs, which use the same CMV promoter and 3 0 -UTR, the protein levels of the PTCH1 isoforms were dramatically different. The amounts of the PTCH1-1B and -1C proteins were remarkably higher compared with those of PTCH1-1 and -1Ckid. Interestingly, the presence of SHH-N reduces protein levels for all isoforms, but this is particularly pronounced for PTCH1-1C. It is notable that the PTCH1-1B protein levels remain high, even in the presence of SHH-N protein. Additionally, inhibition PTCH1 splice variants specific function T Shimokawa et al of protein synthesis by cycloheximide revealed a comparable rate of degradation among the isoforms.
In the presence of SHH-N, this rate of degradation is highest for PTCH1-1C (Supplementary Figure S2) . Moreover, incubation with the proteasome inhibitor MG132 resulted in a dramatic increase in the amounts of PTCH1-1 (Figure 4b) . Thus, the low steady-state levels of PTCH1-1 appear to be due to a particularly high susceptibility to proteasome-mediated degradation. These findings obviously show that the selection of the alternative first exon has a major impact on the amounts of the expressed protein isoforms. Consequently, the strong signaling inhibitory effects of PTCH1-1B and to a lesser extent of PTCH1-1C that were observed in the previous assays appear to be primarily a result of this increased protein expression rather than to major differences in the signaling properties of each of these variant PTCH1 molecules.
Expression of Ptch1 variants during mouse embryogenesis
To elucidate the distinct roles and distribution of the Ptch1 splice variants in embryogenesis, we analysed mouse embryos at 8.5 and 9.5 d.p.c. (days post coitum) by whole-mount in situ hybridization ( Figure 5 ). Riboprobe E2-11 showed the anticipated Ptch1 expression pattern in mouse embryo (E and J). There was strong expression in the neural tube and branchial arches and weak, broader expression was detected around these regions and the gut. Ptch1-1B showed a similar expression pattern as riboprobe E2-11 (C and H). Ptch1-1 also revealed a comparable expression pattern but this was more widely and broadly distributed. By contrast, Ptch1-1A was slightly detected in the blood vessels (B and G). Ptch1-1C showed a strong signal in the yolk sac region (I, white arrowhead) and broad expression all over the embryo as seen with the expression of suppressor of fused (Sufu) (D and I) (Sva¨rd et al., 2006) . Additionally, there was significant expression of Ptch1-1C in the otic placode (I, black arrowhead). These data clearly demonstrate the unique distribution of the Ptch1 variants in mouse embryo and suggest a difference in the role and/or regulation of these isoforms during embryonic differentiation.
Discussion
In this study we have analysed PTCH1 variants generated by the use of alternative promoters and first exons and demonstrated that these may have unique roles in the regulation of HH signaling. Differences in protein stability and in the capacity to act as signaling inhibitors and/or HH receptors as well as a specific tissue distribution during mouse embryogenesis were revealed.
The transcription factors mediating the HH signal, GLI1 and GLI2, are characterized by binding to the same consensus DNA sequence (5 0 -GACCACCCA). Moreover, GLI1, being upregulated by HH signaling activation, may work as a positive feedback regulator and promote signaling. However, recent report (Eichberger et al., 2006) clearly showed that although GLI1 and GLI2 share some target genes they also have numerous independent targets. GLI2, activated by HH signaling, upregulates primary target genes including GLI1, and subsequently GLI1 upregulates secondary target genes (Bai et al., 2002) . In this study, we showed that the PTCH1 isoforms inhibited GLI1 and full-length GLI2, but only partially repressed the active form of GLI2 (Figure 2 ). This suggests that the primary target genes of GLI2 may still be expressed under the partial PTCH1 inhibition. Consequently, the PTCH1 inhibition would be more effective on the secondary, GLI1-dependent targets.
We showed in Figure 4 that the amount of expressed PTCH1 protein was remarkably different depending on which alternative first exon was present in the transfected construct, even though in all cases the same vector backbone was used. PTCH1-1B levels were the highest of all variants and remained high even in the presence of SHH. On the other hand, PTCH1-1C levels, PTCH1 splice variants specific function T Shimokawa et al although also relatively high, were downregulated by SHH to a higher extent than PTCH1-1B, whereas the reduction of the other isoforms appeared to be intermediary. Thus, it is apparent that the unique N-terminal sequence of PTCH1-1B positively influences the stability of the protein. As transcription initiated at exons 1B and 1C, but not at exons 1 or 1A, is known to be upregulated by HH signaling activation (Shimokawa et al., 2004) , it seems that the increased stability of the signaling upregulated protein isoforms is particularly suited for the role of effective inhibitors, acting in the negative feedback loop that is characteristic of this pathway.
We also examined the expression pattern of the Ptch1 variants in mouse embryos ( Figure 5 ). This is the first report that visually shows the distribution of Ptch1 splice variants generated by alternative promoters in the mouse embryo. The similar distribution between the E2-11 and E1B riboprobes may indicate that the Ptch1-1B isoform is the major embryonic transcript. Additionally, the apparent co-localization of Ptch1-1B and SHH (Sva¨rd et al., 2006) suggests that the majority of Ptch1 transcripts in the developing mouse are due to activation by SHH. On the other hand, Ptch1-1 and -1C had a more widespread distribution. Especially Ptch1-1C was found to be present all over the embryo, in similarity to what is seen with Sufu (Sva¨rd et al., 2006) . These two Ptch1 mRNAs encode isoforms that have significant capacities to act as either a receptor or an inhibitor of signaling. This may suggest that Ptch1-1 and -1C repress ectopic activation of the HH signaling pathway without the presence of HH proteins and may also control the response to the appearance of HH. In this analysis, we detected strong signals of the E1C riboprobe in the yolk sac and the otic placode. During the development of the inner ear and the yolk sac, the respective role of SHH and IHH is well established (Liu et al., 2002) . As we could not detect an E1B riboprobe signal in these two structures, Ptch1-1C appears to act as the ligand receptor during development of the yolk sac and the otic placode. This finding raises the novel possibility of tissue-and time-specific HH signaling regulation based on the Ptch1 transcript variants.
Our results support a dynamic cycling model for HH signaling that incorporates the PTCH1 splice variants (Figure 6 ). Regulation in response to HH proteins may involve three states (pre-activation, activation and postactivation). In pre-activation, the PTCH1-1 isoform is expressed. As this variant has sufficient capacity to inhibit endogenous SMO (Figure 3b) , transcription of PTCH1-1B, -1C and GLI1 are repressed. Ligand availability allows the PTCH1-1 isoform to bind HH and act as a functional receptor (Figure 3b ), resulting in signaling activation and upregulation of PTCH1-1B, PTCH1-1C and GLI1 (Shimokawa et al., 2004) . However, the continuous presence of HH protein keeps suppressing the PTCH1-1B and -1C inhibitory activity (Figures 3 and 4) , and sustains significant activation. During this period, the cell accumulating mRNAs for PTCH1-1B and -1C. At the protein level, the increase of PTCH1-1B is more pronounced than PTCH1-1C, as seen in Figure 4 . Termination of ligand availability immediately activates the PTCH1-1B and -1C proteins, and these isoforms inhibit signal transduction at three independent points, SMO, GLI1 and GLI2 (Figures 1d  and 2 ). This model allows for an explanation of the strict switching between activation and inactivation, depending on HH protein levels, and the effective negative feedback loop that regulates HH signal transduction.
Finally, alternative splicing of HH signaling components has also been reported for PTCH2 (Zaphiropoulos et al., 1999; Rahnama et al., 2004) , GLI1 (Wang and Rothnagel, 2001 ) and GLI2 (Speek et al., 2006) . These variants had different protein stabilities and/or biochemical properties. In this study, we clearly demonstrated the unique involvement of the PTCH1 isoforms in HH signal transduction. Further understanding of the complexities of alternative promoters and alternative splicing in HH signaling components will help to rationalize the diverse roles and implications of this ubiquitous signaling pathway.
Materials and methods
Western blotting
At 48 h after transfection, proteins were extracted by lysis buffer (6 M urea, 1% SDS, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 50 mM DTT, 1 Â Complete Protease Inhibitor Cocktail (Roche Diagnostics, Basel, Switzerland)). After normalization based on protein concentration measured by the DC Protein assay kit (Bio-Rad, Hercules, CA, USA), samples were run on a 6 M Urea-SDS acrylamide gel. Thereafter, proteins were transferred onto Hybond-ECL nitrocellulose membrane (GE Healthcare Biosciences, Chalfont St Giles, UK). FLAG-tagged PTCH1 isoforms or b-actin as internal control were determined by the use of anti-FLAG (Stratagene, La Jolla, CA, USA) or anti-b-actin monoclonal antibodies (Sigma, St Louis, MO, USA). HRP-conjugated anti-mouse IgG (GE Healthcare Biosciences, Chalfont, St Giles, UK) was used as the secondary antibody, followed by detection of these proteins with the Western Lightning Western-Blot Chemiluminescence Reagent Plus (PerkinElmer, Wellesley, MA, USA). Quantification was performed by ImageJ (NIH, Bethesda, MD, USA).
